非小细胞癌的分子病理学
1Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
Histopathology
|November 8, 2023
概括
肺癌的治疗方法根据瘤的分子特征而有所不同. 驱动器突变阳性瘤对酶抑制剂有反应,而驱动器突变阴性瘤则受益于免疫检查点抑制剂 (ICI).
科学领域:
- 在瘤学瘤学.
- 分子病理学分子病理学
- 免疫治疗是一种免疫疗法.
背景情况:
- 由于大规模测序和药物开发,肺癌治疗已经取得了重大进展.
- 了解分子病理学揭示了基于驱动器变化的独特特征,影响治疗策略.
- 目前的治疗方法包括传统的化学放射治疗,分子向治疗和免疫检查点抑制剂 (ICI).
研究的目的:
- 解释分子向疗法和ICI在肺癌子集中的差异性疗效.
- 阐明不同肺癌治疗反应背后的分子病原性.
- 应用双分区模型来了解肺癌的发展和治疗目标.
主要方法:
- 对不同肺癌亚组的临床结果进行比较分析 (EGFR/ALK阳性与PD-1/PD-L1阳性).
- 对分子病原学的研究,包括瘤突变负担和免疫监测.
- 应用两个分隔模型来区分肺癌的起源 (终端呼吸单元与空气导管系统).
主要成果:
- 激酶抑制剂对驱动突变阳性肺瘤有效.
- 免疫检查点抑制剂 (ICI) 在驱动突变阴性肺瘤中显示出有效性.
- 驱动突变导致较低的瘤突变负担和较差的ICI反应,而烟雾诱导的改变可以导致更好的ICI反应.
结论:
- 肺癌治疗疗效与其分子病原和驱动器改变状态密切相关.
- 两部分模型有效地解释了肺癌中不同的分子路径和治疗漏洞.
- 根据分子特征 (如驱动突变和PD-1/PD-L1状态) 定制治疗方法,对于优化患者的治疗结果至关重要.
相关概念视频
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancers Originate from Somatic Mutations in a Single Cell
12.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.0K
Non-Canonical Wnt Signaling Pathways
7.3K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K


